Sarepta stock extends decline as company declines FDA call to withdraw drug

Sarepta Therapeutics stock extended its decline, falling 5% premarket Monday after a 36% drop Friday, as the company refused an FDA request to halt sales of its gene therapy Elevidys. This refusal follows a patient death due to liver failure, which Sarepta clarifies occurred in a Phase 1 trial for a different investigational gene therapy (SRP-9004) for Limb-Girdle Muscular Dystrophy, not Elevidys, asserting no new safety signals for the latter. However, Deutsche Bank, which downgraded Sarepta to sell, deemed the distinction 'semantic' due to shared vector technology, noting the FDA has since placed all LGMD gene therapy trials on clinical hold, intensifying regulatory scrutiny on Sarepta's gene therapy platform.

Analysis

Sarepta Therapeutics (SRPT) is experiencing a severe stock decline, falling 36% on Friday and an additional 5% in premarket trading Monday, driven by a direct conflict with the U.S. Food and Drug Administration. The company has taken the unusual step of refusing a voluntary FDA request to withdraw its Duchenne muscular dystrophy gene therapy, Elevidys, following a patient death. Sarepta's management contends the fatality occurred in a separate Phase 1 trial for an investigational LGMD therapy (SRP-9004) that uses a different dose and manufacturing process, asserting no new safety signals for Elevidys. However, this distinction is being challenged, with Deutsche Bank downgrading the stock to 'sell' and labeling the argument 'semantic' because both treatments utilize the same delivery vector. This view is substantiated by the FDA's subsequent decision to place all of Sarepta's LGMD gene therapy trials on clinical hold, indicating that regulatory concern extends beyond a single drug and may implicate the entire underlying technology platform.

Key Decisions for Investors

• Investors should recognize that the primary risk has shifted from commercial execution to fundamental platform viability and escalating regulatory conflict, warranting a review of exposure to SRPT.
• The Deutsche Bank downgrade to 'sell' based on shared vector technology highlights a critical technical risk; monitor for any further adverse events or regulatory actions across Sarepta's entire gene therapy pipeline, not just Elevidys.
• Sarepta's direct refusal of an FDA request creates significant uncertainty and potential for further punitive regulatory action, so investors should consider trimming positions or implementing hedging strategies until there is clear resolution on the vector's safety profile.